Obesity, metabolic syndrome and sleep apnoea: All pro-inflammatory states

Obesity Reviews

Volumn 8, Issue 2, 2007, Pages 119-127

  Alam, I ^a   Lewis, K ^b,c   Stephens, J W ^b,d   Baxter, J N ^a,d  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c PRINCE PHILIP HOSPITAL   (United Kingdom)

^d MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Inflammation; Metabolic syndrome; Obesity; Obstructive sleep apnoea

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; FATTY ACID; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; RESISTIN;

ABDOMINAL SUBCUTANEOUS FAT; ADIPOSE TISSUE; BODY MASS; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; HORMONE RELEASE; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SLEEP APNEA SYNDROME; SLEEP DISORDERED BREATHING; STRESS; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LEPTIN; METABOLIC SYNDROME X; NF-KAPPA B; OBESITY; RISK FACTORS; SLEEP APNEA SYNDROMES;

EID: 33846906889     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2006.00269.x     Document Type: Review

References (107)

1. Lara MD, Kothari SN, Sugerman HJ. Surgical management of obesity. Treat Endocrinol 2005; 4: 55-64.
2. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003; 134: 18-27.
3. Sugerman HJ, DeMaria EJ. Mastery of Surgery, Vol. 1, 4th edn. Philadelphia: Lippincott, Williams & Wilkins, 2001.
4. Reaven GM. Banting lecture. Role of insulin in human disease. Diabetes 1988; 37: 1595-1607.
5. Svatikova A, Wolk R, Gami AS, Pohanka M, Somer VK. Interaction between obstructive sleep apnoea and the metabolic syndrome. Curr Diab Rep 2005; 5: 53-58.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
7. Adami GF, Ravera G, Marinari GM, Camerini G, Scopinaro N. Metabolic syndrome in severely obese patients. Obes Surg 2001; 6: 9-12.
8. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
9. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002; 60 (10 Pt 2): S1-S14;discussion: S68-S84, 85-87.
10. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
11. Wilson PWF, Grundy SM. The metabolic syndrome: a practical guide to origins and treatment. Part II. Circulation 2003; 108: 1537-1540.
12. Tai ES, Demissie S, Cupples LA, Corella D, Wilson PW, Schaefer EJ, Ordovas JM. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22: 805-810.
13. Vega GL, Clark LT, Tang A, Marcovina S, Grundy SM, Cohen JC. Hepatic lipase activity is slower in African American men than in white American men: 5′ flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res 1998; 39: 228-232.
14. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetabologia 1976; 12: 563-571.
15. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low-density lipoprotein production in humans. J Clin Invest 1995; 95: 158-166.
16. Riches FM, Watts GF, Naoumova R et al. Hepatic secretion of very-low-density apolipoprotein B-100 studies with stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998; 22: 414-423.
17. Bosello O, Zamboni M. Visceral obesity and the metabolic syndrome. Obes Rev 2000; 1: 47-56.
18. Muredach PR, Daniel JR. The metabolic syndrome: more than the sum of its parts. Circulation 2003; 108: 1546-1551.
19. Montague CT, O'Rahilly S. The perils of portliness. Causes and consequences of visceral obesity. Diabetes 2000; 49: 883-888.
20. Boyko EJ, Leonetti DL, Fujimoto WY, Newell-Morris L. Visceral obesity and risk of type II diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 2394: 456-471.
21. Banerji MA, Lebowitz J, Chaiken RL et al. Relationship of visceral adipose tissue and glucose disposal is independent of sexing black NIDDM subjects. Am J Physiol 1997; 273E: 425-432.
22. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel). JAMA 2001; 285: 2486-2497.
23. Howard G, Bergman R, Wagenknecht LE, Haffner SM, Savage PJ, Saad MF, Laws A, D'Agostino RB Jr. Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with 'minimal model'. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Ann Epidemiol 1998; 8: 358-369.
24. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002; 13: 18-23.
25. Hanley AJG, Karter AJ, Festa A, D'Agostino RB Jr, Lynne E, Wagenknecht LE, Savage P, Tracy RP, Saad MF, Haffner S. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 2642-2647.
26. Jubber AS. Respiratory complications of obesity. Int J Clin Pract 2004; 58: 573-580.
27. Hoffstein V, Mateika S. Differences in abdominal and neck circumferences in patients with and without sleep apnoea. Eur Respir J 1992; 5: 377-381.
28. Horner RL, Mohiaddin RH, Lowell DG, Shea SA, Burman ED, Langmore DB, Guz A. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. Eur Respir J 1989; 2: 613-622.
29. Grunstein R, Wilcox I, Yang T, Gould Y, Hender J. Snoring and sleep apnea in men: association with central obesity and hypertension. Int J Obesity 1993; 17: 533-540.
30. Shinohara E, Kihara S, Yamashita S, Yamane M, Nishida M, Aria T, Kotani K, Nakamura T, Takemura K, Matsuzawa Y. Visceral fat accumulation as an important risk factor for obstructive sleep apnea syndrome in obese subjects. J Intern Med 1992; 241: 11-18.
31. Coughlin S, Calverley P, Wilding J. Sleep disordered breathing-a new component of syndrome X?. The International Association for the Study of Obesity. Obesity Rev 2001; 2: 735-741.
32. Anstead M, Philips B. The spectrum of sleep-disordered breathing. Respir Care Clin North Am 1999; 5: 363-377.
33. Parish JM, Virend K, Somers VK. Obstructive sleep apnoea and cardiovascular disease. Mayo Clin Proc 2004; 79: 1036-1046.
34. Partinen M. Ischaemic stroke, snoring and obstructive sleep apnoea. J Sleep Res 1995; 4: 156-159.
35. Bixler EO, Vgontzas AN, Lin HM et al. Association of hypertension and sleep disordered breathing. Arch Intern Med 2000; 160: 2289-2295.
36. Carlson JT, Hender JA, Ejnell H, Peterson LE. High prevalence of hypertension in sleep apnea patients independent of obesity. Am J Respir Crit Care Med 1994; 150: 72-77.
37. Elmasry A, Janson C, Lindberg E, Gislason T, Tageldin MA, Boman G. The role of habitual snoring and obesity in development of diabetes: a 10-year follow-up study in male population. J Intern Med 2000; 248: 13-20.
38. Sheehan MT, Jensen MD. Metabolic complications of obesity: pathophysiological consideration. Med Clinc North Am 2000; 84: 363-385.
39. Stradling J, Davies RJ. Sleep apnea and hypertension-what a mess!. Sleep 1997; 20: 789-793.
40. Guilleminault C, Tilkian A, Derment WC. The sleep apnoea syndrome. Annu Rev Med 1976; 27: 465-484.
41. Kales A, Bixler EO, Cadieux RJ, Schneck DW, Shaw LC 3rd, Locke TW, Vela-Bueno A, Soldatos CR. Sleep apnoea in hypertensive population. Lancet 1984; 2: 1005-1008.
42. Fletcher EC, DeBehnke RD, Lovoi MS, Gorin AB. Undiagnosed sleep apnoea in patients with essential hypertension. Ann Intern Med 1985; 103: 190-195.
43. Lave P, Ben JR, Rubin AE. Prevalence of sleep apnoea. Am Heart J 1984; 108: 373-376.
44. Stepniakowski KT, Sallee FR, Goodfriend TR, Zhang Z, Egan BM. Fatty acids enhance neurovascular reflex responses by effects on α1-adrenoreceptors. Am J Physiol 1996; 270 (6 Pt 2): R1340-R1346.
45. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1995; 94: 1172-1179.
46. Davda RK, Stepniakkowski K, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension 1995; 26: 764-770.
47. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
48. Zinman B, Habley AJG, Harris SB, Kwan J, Fantus IG. Circulating tumour necrosis factor-α. Concentration in native Canadian population with high rates of type II diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 272-278.
49. Lavia P, Herer P, Hoffstein V. Obstructive sleep apnea syndrome as a risk factor for hypertension: population study. BMJ 2000; 160: 2289-2295.
50. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep - disordered breathing, sleep apnea, and hypertension in large community-based study. JAMA 2000; 283: 1829-1836.
51. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-1384.
52. Sleight P. Role of baroreceptor reflexes in circulatory control with particular reference to hypertension. Hypertension 1991: 18: III31-III34.
53. Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implication for hypertension. J Hypertens 1997; 15: 1613-1619.
54. Landsberg L. Insulin sensitivity in the pathogenesis and hypertensive complications. Clin Exp Hypertens 1996; 18: 337-346.
55. Stradling JR, Pepperall JCT, Davies RJO. Sleep apnoea and hypertension: proof at last. Thorax 2001; 56: 45-49.
56. Ip MS, Lamb B, Ng MM, Lamb WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-676.
57. Punjabi NM. Improvement of metabolic function in sleep apnea: the power of positive pressure. Am J Resp Crit Care Med 2004; 169: 139-140.
58. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knop RH, Khan SE. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003; 52: 172-179.
59. Hellmer J, Marcus C, Sonnenfeid T, Arner P. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Eendocrinol Metab 2001; 75: 15-20.
60. Freid SK, Russell CD, Grauso NL, Brolin RE. Lipoprotein lipase regulation by insulin and glucocorticoid in the subcutaneous and omental adipose tissue of obese women and men. J Clin Invest 1990; 92: 2191-2198.
61. Arner P, Hellstorm L, Wahrenberg H, Bronnegard M. Betadrenoreceptor expression in human fat cell from different regions. J Clin Invest 1990; 86: 1595-1600.
62. Zierath J, Livingston J, Thorne A, Bolinder J, Reynisdottir S, Lonnqvist F, Arner P. Regional differences in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and insulin signaling through the insulin receptor substrate - 1 pathway. Diabetolgia 1998; 41: 1343-1354.
63. Mittleman SD, Gregg W, Van Cltters Erlinda L, Kirkman EL, Bergmann NR. Extreme insulin resistance of central obesity depot in vivo. Diabetes 2002; 51: 755-761.
64. Paulmyer-Lacroix O, Boullu S, Oliver C et al. Expression of the mRNA coding for II β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patient: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-2705.
65. Joyner J, Hultley L, Cameron D. Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes. Horm Metab Res 2002; 34: 223-228.
66. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109: S135-S148.
67. Vikman HL, Savola JM, Raasmaja A, Ohisalo JJ. 2A adrenergic regulation of cyclic AMP accumulation and lipolysis in human omental and subcutaneous adipocytes. Int J Obes 1996; 20: 185-189.
68. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000; 11: 212-217.
69. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-3265.
70. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008-2014.
71. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, Schauer PR. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 2004; 14: 589-600.
72. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919;quiz 920.
73. Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M. The 174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 2003; 52: 558-561.
74. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158.
75. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6 but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
76. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-812.
77. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
78. Fernandez-Real JM, Ricart W. [An increased proinflammatory activity is inherent in insulin resistance]. Med Clin (Barc) 2000; 115: 185-189.
79. Vozarova B, Fernandez-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, Wolford JK. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003; 112: 409-413.
80. Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Mantzoros CS. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 2003; 11: 1048-1054.
81. Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2000; 87: 2084-2089.
82. Clarke D, Mohamed-Ali V. The role of interleukin-6 in adipogenesis (Abstract). Endo: 1213.
83. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin resistant subjects. J Biol Chem 2003; 278: 45777-45784. Epub 2003.
84. Stephens JW, Hurel SJ, Acharya J, Humphries SE. An interaction between the interleukin-6-174G>C gene variant and urinary protein excretion influences plasma oxidative stress in subjects with type 2 diabetes. Diabetes 2002; 3: 2.
85. Roytblat L, Rachinsky M, Fisher A, Gremmberg L, Shapira Y, Douvdevani A, Gelam S. Raised interleukin-6 levels in obese patients. Obes Res 2000; 8: 673-675.
86. Maffei M, Fei HG, Lee GH, Dani C, Leroy P, Zhang Y, Proenca R, Negrel R, Ailhaud G, Friedman JM. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci USA 1995; 92: 6957-6960.
87. Pannacciulli N, Vettor R, Milan G, Granzotto M, Catucci A, Federspil G, DeGiacomo P, Giorgino R, De Pergola G. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 2003; 88: 1748-1752.
88. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184.
89. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316: 924-929.
90. Antje K, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to more. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-546.
91. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
92. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puiga A, Considine RV, O'Rhilly S. Resistin/FIZZ3 expression in relation to obesity, a peroxisome proliferators-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202.
93. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-11256.
94. Shetty GK, Economides PA, Horton ES et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
95. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Radar DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.
96. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκBα. Diabetes 2002; 51: 2005-2011.
97. Paul P, Gary S, Firestein. NF-KB A key role in inflammatory process. J Clin Invest 2001; 107: 7-11.
98. Albert S, Baldwin J. Series introduction: the transcription factor NF-κB and human disease. J Clin Invest 2001; 107: 3-6.
99. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Steven SE, Shulman GI. Mechanism by which highdose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-1326.
100. Semenza GL. Hypoxia inducible factor 1: oxygen haemostsis and disease pathophysiology. Trends Mol Med 2001; 7: 345-350.
101. Cherniack NS. Inflammatory ideas about sleep apnoea. Respiration 2004; 71: 20-21.
102. Imagawa S, Yamaguchi Y, Ogawa K, Suzuki N, Yamamoto M, Nagasawa T. Interleukin 6 and tumour necrosis factor-alphain patients with obstructive sleep apnoea-hypopnoea syndrome. Respiration 2004; 71: 20-29.
103. Hatipoglu U, Rubenstein I. Inflammation and obstructve sleep apnoea syndrome pathogensis: a working hypothesis. Respiration 2003; 70: 665-671.
104. Yun AJ, Lee PY, Bazar KA. Autonomic dysregulation as a basis of cardiovascular disturbances associated with obstructive sleep apnoea and other conditions of chronic hypoxia, hypercapnia and acidosis. Med Hypothesis 2004; 62: 852-856.
105. Harsh IA, Koebnick C, Wallaschofski H, Schahin SP, Hahn EG, Ficker JH, Lohman T, Konturek PC. Resistin levels in patients with obstructive sleep apnoea syndrome-the link to subclinical inflammation. Med Sci Monit 2004; 10: CR510-CR515.
106. Harsch IA, Hahn EG, Konturek PC. Insulin resistance and other metabolic aspects of the obstructive sleep apnoea syndrome. Med Sci Monit 2005; 11: RA70-RA75.
107. van Dielen FM, van't veer C, Schols AM, Soeters PB, Buurman WA, Greve JW. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001; 25: 1759-1766.